drugset
drugset / Trial / NCT05874180

A Pharmacokinetic Study of DW6013 (FDC of Linagliptin and Metformin) in Healthy Adult Volunteers in Fed Condition

NCT05874180 ↗

Phase 1 Completed 31 enrolled Dong Wha Pharmaceutical Co. Ltd.
RandomizedCrossoverOpen-labelTreatment

Summary

This study is to compare and evaluate the safety and pharmacokinetic characteristics (PK) after administration of DW6013 and each component in healthy adult volunteers in fed condition.

Timeline

Start
2023-01-09
Primary completion
2023-02-01
Completion
2023-02-03

Drugs

EvaluationDrugModalityDoseRoute
Subject Linagliptin Small molecule — Oral
Subject Metformin Small molecule — Oral

Indications

No indication recorded.